Invitrogen's plan to spend half a billion dollars on acquisitions in 2006 remains on track, Chairman and CEO Greg Lucier said during a conference call last week, despite what he views as higher premiums being paid for acquisition targets.

Lucier also said during the call, which followed the release of Invitrogen's first-quarter results, that the firm believes the BioReliance business, which has struggled over the last year, will recover and return to positive sales growth this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.